首荟通便胶囊联合莫沙必利对功能性便秘患者血清SP、MTL、NO水平及生活质量的影响

摘要 目的：探讨首荟通便胶囊联合莫沙必利对功能性便秘患者血清P物质（SP）、胃动素（MTL）、一氧化氮（NO）水平及生活质量的影响。方法：选取2018年3月~2020年2月期间我院接收的功能性便秘患者127例，随机分为对照组（n=63，莫沙必利治疗）和研究组（n=64，首荟通便胶囊联合莫沙必利治疗），对比两组疗效、症状评分、生活质量及血清SP、MTL、NO水平，记录两组治疗期间不良反应情况。结果：对照组治疗4周后的总有效率为77.78%（49/63），低于研究组治疗4周后的90.63%（58/64）（P<0.05）。两组治疗4周后排便困难、粪便性状、排便间隔、排便不尽感评分均较治疗前下降，且研究组低于对照组（P<0.05）。两组治疗4周后心理功能、躯体功能、社会功能、物质生活状态评分均较治疗前升高，且研究组高于对照组（P<0.05）。两组治疗4周后血清SP、MTL高于治疗前，且研究组较对照组更高（P<0.05），血清NO比治疗前更低，且研究组较对照组更低（P<0.05）。两组均未见明显不良反应发生。结论：在莫沙必利基础上，联合首荟通便胶囊治疗功能性便秘患者，能较好的减轻临床症状，缓和不良体征，促进生活质量改善，疗效确切，其作用机制可能与调节血清SP、MTL、NO水平有关。

Effect of Shouhui Tongbian Capsule Combined with Mosapride on Serum SP, MTL, NO Levels and Quality of Life in Patients with Functional Constipation

ABSTRACT Objective: To investigate the effect of Shouhui Tongbian capsule combined with mosapride on serum substance P (SP), motilin (MTL), nitric oxide (NO) and quality of life in patients with functional constipation. Methods: 127 patients with functional constipation in our hospital from March 2018 to February 2020 were selected, and randomly divided into control group (n=63, mosapride treatment) and study group (n=64, Shouhui Tongbian capsule combined with Mosapride treatment). The efficacy, symptom score, quality of life, serum SP, MTL, NO levels of the two groups were compared, and the adverse reactions of the two groups during treatment were recorded. Results: The total effective rate of the control group after 4 weeks of treatment was 77.78%(49/63), which was lower than 90.63%(58/64) of the study group after 4 weeks of treatment. 4 weeks after treatment, the defecation difficulty, stool characteristics, defecation interval and incomplete defecation scores of the two groups decreased compared with those before treatment, and the study group was lower than the control group(P<0.05). 4 weeks after treatment, the scores of psychological function, physical function, social function and material life state of the two groups were higher than those before treatment, and the study group was higher than the control group (P<0.05). 4 weeks after treatment, serum SP and MTL of the two groups were higher than those before treatment, and the study group was higher than the control group(P<0.05), and serum NO was lower than that before treatment, and the study group was lower than the control group(P<0.05). No obvious adverse reactions occurred in both groups. Conclusion: On the basis of Mosapride, combined with Shouhui Tongbian capsule in the treatment of functional constipation patients, can better alleviate clinical symptoms, alleviate adverse signs, promote the improvement of quality of life, which has definite curative effect, the mechanism may be related to the regulation of serum SP, MTL, NO levels.